Indivior Pharmaceuticals Inc (NAS:INDV)
$ 38.83 +0.14 (+0.36%) Market Cap: 4.58 Bil Enterprise Value: 4.87 Bil PE Ratio: 13.92 PB Ratio: 0 GF Score: 81/100

Half Year 2025 Indivior PLC Earnings Call Transcript

Jul 31, 2025 / 12:00PM GMT
Release Date Price: $20.2 (+16.09%)

Key Points

Positve
  • Indivior PLC (INDV) reported record net revenue for Sublocade, driven by strong performance in the US market.
  • The company raised its full-year 2025 net revenue guidance and profit expectations, indicating confidence in future performance.
  • Sublocade's market share in the US remained stable at approximately 75%, with growth in the number of active prescribers.
  • Indivior PLC (INDV) is implementing a multi-year operational roadmap, the Indivior action agenda, to maximize business potential and shareholder value.
  • The company is focused on improving commercial execution and simplifying operations to reduce costs and enhance efficiency.
Negative
  • Indivior PLC (INDV) acknowledges that US commercial execution needs improvement, indicating potential challenges in market penetration.
  • The company faces pricing pressure on Suboxone film, which could impact future revenue.
  • There is complexity in operations with nonessential activities inflating the cost structure, necessitating a focus on simplification.
  • The company is undergoing a transition year, which may involve uncertainties and adjustments in strategy and operations.
  • Indivior PLC (INDV) is delisting from the London Stock Exchange, which may have implications for its investor base and market presence.
Jason Thompson Indivior;Vice President Investor Relations

Thank you and good morning and Welcome to The Indivior Second Quarter 2025 earnings conference call. I'm joined today by Joe Schon, Chief Executive Officer, Patrick Berry, Chief Commercial Officer, Christian Heidbreder, Chief Scientific Officer, and Ryan Preblick, our Chief Financial Officer.

Before we begin, I need to remind everyone that on today's call, we may make forward-looking statements that are subject to risks and uncertainties and that actual results may differ materially. We list the factors that may cause our results to be materially different here on slide two of this presentation.

We also may refer to non-gap measures, the reconciliations for which may also be found in the appendix to this presentation that is now posted on our website at endevior.com. I'll now turn the call over to Joe.

Joseph Ciaffoni
Indivior PLC - Chief Executive Officer, Director

Thanks, Jason. Good morning and thank you everyone for joining the call. Today I will start with an overview of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot